RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost immune attack on HPV-Driven head and neck cancer
Disease control OngoingThis Phase 3 trial tests whether adding an experimental immunotherapy called PDS0101 to the standard drug pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer. About 252 participants will receive either the combination or pembrolizumab alone. T…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis phase 2 trial tests whether adding ramucirumab to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1 positive head and neck cancer that has come back or spread. About 37 participants will receive either the combination or the single drug. Th…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New trial tests shorter radiation for head and neck cancer that has returned
Disease control TerminatedThis phase II trial compares two types of radiation for people whose head and neck cancer has come back and cannot be removed with surgery. One method delivers high-dose radiation in fewer sessions, while the other uses standard daily doses over several weeks. The study aims to s…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC